Pathology: mNSCLC - L1 - PDL1 positive; mNSCLC - L2 - all population; mNSCLC - L2 - PDL1 positive;
| mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - all population | mNSCLC - L2 - PDL1 positive | |||||
| IMpower-110 (TC2/3 or IC2/3), 2020 | IMpower-110 (TC1/2/3 or IC1/2/3), 2020 | IMpower-110 (TC3 or IC3), 2020 | OAK (all population), 2016 | POPLAR, 2016 | OAK (PDL1 TC 1/2/3), 2016 | ||
| atezolizumab alone | 6 | T1 | T1 | T1 | T1 | T1 | T1 |
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | |||
| docetaxel | 0 | T0 | T0 | T0 | |||